Global patent index - EP 0967976 A1

EP 0967976 A1 2000-01-05 - THE USE OF PROTEASOME INHIBITORS FOR TREATING CANCER, INFLAMMATION, AUTOIMMUNE DISEASE, GRAFT REJECTION AND SEPTIC SHOCK

Title (en)

THE USE OF PROTEASOME INHIBITORS FOR TREATING CANCER, INFLAMMATION, AUTOIMMUNE DISEASE, GRAFT REJECTION AND SEPTIC SHOCK

Title (de)

DIE VERWENDUNG VON PROTEASOM HEMMERN ZUR BEHANDLUNG VON KREBS, ENTZÜNDUNG, AUTOIMMUNKRANKHEITEN, TRANSPLANTABSTOSSUNG UND SEPTISCHEM SCHOCK

Title (fr)

UTILISATION D'INHIBITEURS DE PROTEASOMES DANS LE TRAITEMENT DU CANCER, DE L'INFLAMMATION, DE MALADIES AUTOIMMUNES, DU REJET DU GREFFON ET DU CHOC SEPTIQUE

Publication

EP 0967976 A1 (EN)

Application

EP 98951135 A

Priority

  • CA 9801010 W
  • CA 2219867 A

Abstract (en)

[origin: WO9922729A1] The present invention relates to compositions comprising proteasome inhibitors, such as lactocystin and analogues thereof. These compositions are used for the following purposes: (1) to disrupt mitochondrial function (useful against cancer, inflammation, adverse immune reaction and hyperthyroidism), (2) to disrupt nitric oxide synthesis (useful against inflammation and septic shock), and (3) to reverse ongoing adverse immune reactions, such as autoimmune diseases and graft rejection. In the later case, the compositions are administered once the patient's T cells are mostly activated. Proteasome inhibitors can also be combined to immuno-suppressive drugs like rapamycin, cyclosporin A and FK506. Finally, a method for screening a compound having a proteasome inhibition activity is also disclosed and claimed.

IPC 1-7 (main, further and additional classification)

A61K 31/40

IPC 8 full level (invention and additional information)

A61K 45/00 (2006.01); A61K 31/00 (2006.01); A61K 31/40 (2006.01); A61K 31/4015 (2006.01); A61K 31/436 (2006.01); A61K 31/445 (2006.01); A61K 31/7042 (2006.01); A61K 38/13 (2006.01); A61P 5/14 (2006.01); A61P 29/00 (2006.01); A61P 35/00 (2006.01); A61P 37/06 (2006.01)

CPC (invention and additional information)

A61K 31/436 (2013.01); A61K 31/00 (2013.01); A61K 31/40 (2013.01); A61K 31/445 (2013.01); A61K 38/13 (2013.01); G01N 2333/96425 (2013.01)

Combination set (CPC)

  1. A61K 31/40 + A61K 2300/00
  2. A61K 31/436 + A61K 2300/00
  3. A61K 31/445 + A61K 2300/00
  4. A61K 38/13 + A61K 2300/00

Citation (search report)

See references of WO 9922729A1

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

EPO simple patent family

WO 9922729 A1 19990514; AU 770798 B2 20040304; AU 9731898 A 19990524; CA 2219867 A1 19990430; EP 0967976 A1 20000105; JP 2001508465 A 20010626

INPADOC legal status

2004-10-13 [18R] REFUSED

- Effective date: 20040521

2001-11-21 [17Q] FIRST EXAMINATION REPORT

- Effective date: 20011009

2000-03-29 [RAP1] TRANSFER OF RIGHTS OF AN EP APPLICATION

- Owner name: CENTRE DE RECHERCHE DU CENTRE HOSPITALIER DE L'UNI

2000-03-29 [RAP1] TRANSFER OF RIGHTS OF AN EP APPLICATION

- Owner name: UNIVERSITE DE MONTREAL

2000-01-05 [17P] REQUEST FOR EXAMINATION FILED

- Effective date: 19990629

2000-01-05 [AK] DESIGNATED CONTRACTING STATES:

- Kind Code of Ref Document: A1

- Designated State(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE